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Abstract
The aim of this study is to investigate if retrieval of 12 lymph nodes (LNs) is sufﬁcient to avoid stage migration as well as to evaluate the
prognostic impact of insufﬁcient LN retrieval in different treatment settings of rectal cancer, particularly in the case of preoperative
chemoradiotherapy (pCRT).
The data of all patients with biopsy proven rectal adenocarcinoma who underwent curative surgery between January 2005 and
December 2012 were analyzed. Univariate and multivariate analyses for oncologic outcomes were performed in LN metastasis or no
LN metastasis (LN) group. Subgroup analyses were performed according to whether a patient had received pCRT.
A total of 1825 patients were enrolled into the study. The maximal Chi-square method revealed the minimum number of harvested
LNs required to be 12. Univariate and multivariate analyses found LNs≥12 to be an independent prognostic factor for both overall
survival (OS) (hazard ratio [HR]=0.5, 95% conﬁdence intervals [CIs]: 0.3–0.8; P=0.002) and disease-free survival (DFS) (HR=0.6,
95%CI: 0.4–0.7; P<0.001) in the LN group. In the LN group, LNs≥12 continued to be a signiﬁcant prognostic factor both for OS
and DFS in the subgroup of patients who did not undergo pCRT. However, in the subgroup of the LN patients who underwent
pCRT, LN≥8 was signiﬁcant for DFS and OS.
Retrieval of LNs≥12 and LNs≥8 should be achieved to obtain accurate staging and optimal treatment for the non-pCRT and
pCRT groups in rectal cancer, respectively.
Abbreviations: CEA = carcinoembryonic antigen, CI = conﬁdence interval, CT = computed tomography, DFS = disease-free
survival, HR = hazard ratio, LN = lymph node, OS = overall survival, pCRT = preoperative chemoradiotherapy.
Keywords: lymph node, preoperative chemoradiotherapy, rectal cancer, stage migration1. Introduction
Colorectal cancer is the 3rd most common cause of cancer death
in the USA,[1] and in Korea the incidence of colorectal cancer has
rapidly increased by 5.2% over the past 10 years. Locally,
colorectal cancer is the 2ndmost common cancer inmales and the
3rdmost common in females.[2] Furthermore, in Korea, mortality
from colorectal cancer is 3rd most common in males and 2nd
most common in females.[2]
The prognosis for colorectal cancer is primarily determined by
the tumor–node–metastasis (TNM) stage of the disease. The
currently most widely accepted staging system for colorectalEditor: Sergio Huerta.
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1cancer – the 7th American Joint Committee on Cancer staging
system – is based on the number of metastatic lymph nodes (LNs)
present as well as the pathologic T-stage.[3] Based on many
reports, positive LN metastases have been well established as one
of the most signiﬁcant risk factors affecting recurrence and
survival in colorectal cancer.[4,5]
Accurate diagnosis of the extent of disease is essential in the
treatment of anymalignancy, and rectal cancer is of no exception.
Insufﬁcient retrieval of LNs may result in stage migration,
subsequently leading to suboptimal treatment – which may
explain survival discrepancies between patients in the same stage
of disease. Speciﬁcally, the possibility of stage migration is
increased when the insufﬁcient number of LNs have been
harvested after resection and where no metastatic LNs have been
found. The importance of the number of harvested LNs on
outcomes of colorectal cancer has been identiﬁed in population-
based and clinical studies.[6,7] Although the current staging
system recommends adequate number of harvested LNs of 12 or
more, it disregards the location of the tumor being in the colon or
rectum and the potential effect of different treatment strategies.
Recently, preoperative chemoradiotherapy (pCRT) has become
the standard approach for locally advanced rectal cancer.[8] Since
pCRT potentially induces LN regression, the chance of harvest-
ing an inadequate number of LNs following surgery may
increase.[9]
Furthermore, the data supporting this recommendation is
based primarily on studies of patients undergoing surgery for
colon cancer.[10] In patients with rectal cancer, studies have
Figure 1. Overview of patient population in the study.
Han et al. Medicine (2016) 95:38 Medicineshown that the LN harvest may be less compared to colon
cancer,[11] and as such the extent to which this indicative value of
12 LNs should be extrapolated to rectal cancer is certainly
questionable.
For rectal cancer, despite guidelines suggesting 12 LNs to be
the minimum requirement for the accurate assessment of LN
status, opinions on the optimal number of harvested nodes differ
between studies and varies according to different treatment
settings.[12] The aim of this study is to investigate if 12 LNs are
sufﬁcient to avoid stage migration and to evaluate the prognostic
impact of insufﬁcient LN retrieval in different treatment settings
of rectal cancer.
2. Materials and methods
2.1. Patient enrollment
The medical records of the patients with biopsy proven rectal
adenocarcinoma who underwent curative surgery between
January 2005 andDecember 2012were retrospectively reviewed.
We excluded patients who underwent emergency operations,
those with distant metastasis, lateral pelvic node dissection, and
no available follow up data. A total of 1825 patients who met the
enrollment criteria were divided into 2 groups with or without
pCRT (Fig. 1).
2.2. Treatment and follow-up strategies
American Joint Committee on Cancer classiﬁcation 7th edition[3]
was used for staging. Clinical stage was determined based on
preoperative examination by chest radiography and/or chest
computed tomography (CT) scan, abdominal and pelvic CT scan,
transrectal ultrasonography, and/or pelvic magnetic resonance
imaging (MRI). The pathologic examination was reported in
standardized manner by qualiﬁed pathologists. Pathologic
ﬁndings also described tumor differentiation, vascular invasion,
lymphatic invasion, and resection margin in all specimens in
addition to the T and N staging. Management of patients was
discussed in multidisciplinary team meeting as necessary before
commencement of treatment. Patients with clinically staged T3 or2N1 disease received pCRT. In our institution, pCRT consists of 5-
ﬂuorouracil (5-FU)-based chemotherapy and pelvic irradiation
(4500–5040cGy) delivered in 25 fractions of 180cGy/day over 5
weeks. Curative resection was performed 6 to 8 weeks after
completion of pCRT and all patients received surgical resection
based on the principles of total mesorectal excision (TME).
Patients who underwent curative surgery were subjected to a
standard follow-up program. Rectal examinations and serum
carcinoembryonic antigen (CEA) measurements were carried out
whenever the patient visited the outpatient clinic. Contrast-
enhanced helical CT was performed every 6 months during the
follow-up period, andMRI or positron emission tomography-CT
was performed if needed.2.3. Data analysis and statistical analyses
The primary outcome was disease-free survival (DFS) and overall
survival (OS). DFS was deﬁned as the time between date of
surgery and date of recurrence. Recurrence included local,
regional, and distant failures. Local and distant recurrences were
conﬁrmed radiologically or histologically by qualiﬁed radiol-
ogists and pathologists. OS was deﬁned as the time between the
date of surgery and the date of death or last follow-up. This study
was approved by the institutional review board and informed
consent was waived.
Statistical analysis was performed using SPSS version 20.0
(IBM corp., Armonk, NY) and R version 3.2.2 (The R
Foundation for Statistical Computing Platform, Vienna, Austria)
after patient-identiﬁers were removed from the dataset. Differ-
ences between categorical variables were compared using the x2
test. TheWilcoxon rank sum test or t test was used for continuous
variables by Shapiro–Wilk normality test. The Kaplan–Meier
method was used to estimate OS and DFS with the log-rank test
to compare factors. Multivariate Cox proportional hazard
analysis was used to identify factors associated with DFS and
OS.[13] A P value of<0.05was considered statistically signiﬁcant.3. Results
3.1. Patient clinical characteristics
A total of 1825 patients were enrolled in the study. There were
1159 (63.5%) men and 666 (36.5%) women, with a median age
of 60 (range, 22–99 years). The minimum required harvested LN
number was decided using maximal Chi-square method.[14] The
cut-off value of 12 LNs was determined by the maximal Chi-
square method based on survival data (M=3.2926, P=0.02).
Based on this number, the patients were divided into 2 groups,
group A (<12 LNs) and group B (≥12 LNs). Clinical character-
istics and pathological variables were compared accordingly.
Patients in group A were more likely to be of older age (P<
0.001). Tumor location of group A was more likely to be located
in lower rectum than group B (38.1% vs 26.3%, P<0.001).
More patients in group A were treated by pCRT than group B
(41.2% vs 35.3%, P<0.001). A lower concentration of
preoperative CEA was found in group A (82.3% vs 70.7%,
P<0.001). The median follow-up was 52 months.3.2. Pathologic characteristics with distribution of lymph
nodes
The median number of LNs harvested was 15 (interquartile
range [IQR], 10–22). In total, 1242 (68.1%) of patients had
Table 1
Clinicopathologic characteristics.
Total <12 LNs (N=583) ≥12 LNs (N=1242) P
Age, years 60.0 [52.0;68.0] 62.0 [54.0;70.0] 59.0 [51.0;67.0] <0.001
Sex 0.979
Male 1159 (63.5%) 371 (63.6%) 788 (63.4%)
Female 666 (36.5%) 212 (36.4%) 454 (36.6%)
ASA 0.491
1 945 (51.8%) 289 (49.6%) 656 (52.8%)
2 798 (43.7%) 265 (45.5%) 533 (42.9%)
3 77 (4.2%) 28 (4.8%) 49 (3.9%)
4 5 (0.3%) 1 (0.2%) 4 (0.3%)
CRT <0.001
None 658 (63.1%) 247 (42.4%) 411 (33.1%)
Preoperative CRT 679 (37.2%) 240 (41.2%) 439 (35.3%)
Postoperative CRT 488 (26.7%) 96 (16.5%) 392 (31.6%)
CEA, ng/mL <0.001
5< 1344 (74.4%) 474 (82.3%) 870 (70.7%)
5≥ 463 (25.6%) 102 (17.7%) 361 (29.3%)
Preoperative symptom 0.056
None 1776 (97.3%) 574 (98.5%) 1202 (96.8%)
Bleeding 6 (0.3%) 2 (0.3%) 4 (0.3%)
Obstruction 29 (1.6%) 3 (0.5%) 26 (2.1%)
Perforation 14 (0.8%) 4 (0.7%) 10 (0.8%)
Tumor location <0.001
Lower 549 (30.1%) 222 (38.1%) 327 (26.3%)
Middle 956 (52.4%) 267 (45.8%) 689 (55.5%)
Upper 320 (17.5%) 94 (16.1%) 226 (18.2%)
Total LN 15.0 [10.0;22.0] 7.0 [4.0;10.0] 19.0 [15.0;26.0] <0.001
LN metastasis <0.001
Negative 1208 (66.2%) 461 (79.1%) 747 (60.1%)
Positive 617 (33.8%) 122 (20.9%) 495 (39.9%)
pTMN <0.001
pCR 57 (3.1%) 31 (5.3%) 26 (2.1%)
1 729 (39.9%) 307 (52.6%) 422 (33.9%)
2 422 (23.2%) 123 (21.2%) 299 (24.1%)




Low 1632 (89.4%) 503 (86.3%) 1129 (90.0%)
High 136 (7.5%) 49 (8.4%) 87 (7.9%)
Others† 57 (3.1%) 31 (5.3%) 26 (2.1%)
LVI <0.001
Negative 1418 (81.2%) 479 (87.4%) 939 (78.3%)
Positive 329 (18.8%) 69 (12.6%) 260 (21.7%)
Continuous variables expressed as median and interquartile range (IQR 25%–75%). ASA=American Society of Anesthesiology, CEA= carcinoembryonic antigen, CRT=chemoradiotherapy, LN= lymph node,
LVI= lymphovascular invasion, pCR=pathologic complete remission, pTNM=pathological tumor–node–metastasis.
∗
Low: well or moderately differentiated; High: poorly differentiated or mucinous carcinoma.
† No residual tumor after pCRT.
Han et al. Medicine (2016) 95:38 www.md-journal.comLNs≥12 retrieved. The pathologic complete remission (pCR)
rate after pCRT was signiﬁcantly different between the groups
(group A: 5.3% vs group B: 2.1%, P<0.001). Lymphovascular
invasion was less frequent in group A compared to group B (P<
0.001). There were 461 (79.1%) stage I/II patients in group A,
but 747 (60.1%) stage I/II patients in group B (p<0.001).
Tumor grading showed no signiﬁcant differences between the
groups. The clinicopathologic characteristics are shown in
Table 1.3.3. Survival in relation to harvested number of lymph
nodes
Median DFS was 42 (range, 0–114) months in group A and 38
(range, 0–113) months in group B (P=0.91). Median OS was 49
(range, 0–114) months in group A and 46 (range, 0–113)3months in group B (P=0.89). In the patients with metastatic LNs
(n=617), no signiﬁcant difference in DFS (58% vs 56%, P=
0.383) and OS (73% vs 67%, P=0.061) was observed in
between group A and B. On the other hand, in patients without
metastatic LN (n=1208), a signiﬁcant difference in DFS (80% vs
86%, P=0.001) and OS (85% vs 92%, P=0.001) was observed
in between group A and B (Fig. 2).
Patients without metastatic LNs were then further divided
into those who did and did not undergo pCRT (Fig. 3). In the
group without pCRT (n=750), a signiﬁcant difference in DFS
(86% vs 91%, P=0.037) and OS (89% vs 94%, P=0.006) was
observed in between group A and group B. In the pCRT group
(n=458), a signiﬁcant difference in DFS (71% vs 80%, P=
0.019) was observed in between group A and group B.
However, there was no signiﬁcant difference in OS (81% vs
88%, P=0.054).
Figure 2. Disease-free survival and overall survival for 1208 patients with node negative.
Han et al. Medicine (2016) 95:38 Medicine3.4. Risk factor analysis in patients without metastatic
lymph nodes
We performed uni- and multivariate analyses for the factors
associated to DFS and OS in the patients without metastatic LNs
(Tables 2, 3). On univariate analysis, LN≥12, pathological
TNM (pTNM) stage, pCRT, preoperative CEA, and tumor
location were signiﬁcant predictors of DFS. LN≥12, age,
preoperative CEA, pTNM stage, pCRT, tumor location, and
preoperative symptoms were signiﬁcant predictors of OS. On
multivariate analysis, LNs≥12 provided signiﬁcant beneﬁt inFigure 3. DFS and overall survival in patients with pCRT (n=458) or not (n=750)
preoperative chemoradiotherapy.
4DFS compared with LNs<12 (hazard ratio [HR]=0.6, 95%
conﬁdence intervals [CIs]: 0.4–0.7; P<0.001). Tumor location,
pCRT, and pTNM stage were also signiﬁcant independent
predictors of DFS. We detected a signiﬁcant difference in OS
between groups with the number of LNs≥12 and LNs<12 on
multivariate analysis (HR=0.5, 95% CI: 0.3–0.8; P=0.002).
Age, pTNM stage, tumor location, and preoperative symptoms
were signiﬁcant independent predictors of OS.
In the patients with metastatic LNs, sex, lymphovascular
invasion (LVI), preoperative CEA, pCRT, and pTNM stage werein node negative by 12 harvested nodes. DFS=disease-free survival, pCRT=
Table 2
Cox regression hazard ratio for disease-free survival (LNM).
Univariate analysis Multivariate analysis
HR CI (95%) P HR CI (95%) P
LN≥12 0.6 0.4–0.8 0.001 0.6 0.4–0.7 <0.001
pTNM <0.001 <0.001
pCR 1 1
I 0.6 0.2–1.1 0.001 0.8 0.4–1.9 0.001
II 1.5 0.7–3.1 0.001 2.3 1.0–4.8 0.001
III 1.7 0.3–8.2 0.001 1.8 0.3–8.5 0.001
pCRT 0.3 0.2–0.5 0.001 0.6 0.4–0.9 0.014
CEA 1.8 1.3–2.5 0.001 1.1 0.8–1.6 0.462
Tumor location 0.001 0.008
Upper 1 1
Middle 2.5 1.5–4.2 0.001 1.9 1.1–3.3 0.011
Lower 1.4 0.8–2.3 0.156 1.3 0.7–2.1 0.317
CEA= carcinoembryonic antigen, CI= conﬁdence interval, HR=hazard ratio, LN= lymph node, LNM= lymph node metastasis, pCR=pathologic complete remission, pCRT=preoperative chemoradiotherapy,
pTNM=pathological tumor–node–metastasis.
Han et al. Medicine (2016) 95:38 www.md-journal.comsigniﬁcant independent predictors of DFS. In addition, age,
histologic grade, LVI, preoperative symptoms, and pTNM stage
were signiﬁcant independent predictors of OS.However, retrieval
of 12 or more LNs provided no signiﬁcant difference in both DFS
and OS (Tables 4, 5).
3.5. Risk factor analysis in the patients without metastatic
lymph node according to treatment settings
The patients without metastatic LNs were further divided into
pCRT and no pCRT subgroups for further analyses. We
performed uni- and multivariate analyses of the factors
associated with DFS and OS in the patients without pCRT. In
univariate analysis, LN≥12, pTNM stage, LVI, preoperative
CEA, and age were signiﬁcant factors of DFS, and LN≥12, age,
preoperative CEA, pTNM stage, American Society of Anesthesi-
ologists, and LVI were signiﬁcant predictors of OS. In
multivariate analysis, LNs≥12 provided signiﬁcant beneﬁt in
DFS compared with LNs<12 (HR=0.4, 95% CI: 0.2–0.7; P=
0.001). Age and pTNM stage were signiﬁcant independent
predictors of DFS.We detected signiﬁcant independent differenceTable 3
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5in OS between the number of LNs≥12 and LNs<12 on
multivariate analysis (HR=0.4, 95% CI: 0.2–0.7; P=0.002).
Age, pTNM stage, and preoperative CEA were signiﬁcant
independent predictors of OS. In the patients with pCRT, LN≥
12 was a signiﬁcant prognostic factor for DFS on multivariate
analysis (HR=0.6, 95%CI: 0.4–0.9; P=0.021). However, it was
not for OS (HR=0.6, 95% CI: 0.4–1.1; P=0.130).3.6. Analysis for pCRT group without lymph node
metastasis
Because LNs≥12 was not a signiﬁcant factor for OS in the pCRT
group without LN metastasis, we suspected that the number of
LN 12 might not be the optimal requirement in the setting of
pCRT. As such, we performed further analysis for the pCRT
group without LN metastasis to assess the minimum required
harvested LN number using the maximal Chi-square method
based on survival data.[14] On the basis of this method, a cut-off
value of 8 LN was determined (M=3.4591, P=0.015).
A signiﬁcant difference in DFS (69.9% vs 78.6%, P=0.014)
was observed between LNs≥8 and LNs<8. Furthermore, aMultivariate analysis
P HR CI (95%) P
0.001 0.5 0.3–0.8 0.002
<0.001 1.1 1.02–1.06 <0.001
<0.001 <0.001
1
0.001 1.2 0.3–4.0 0.001
0.001 3.3 1.0–10.8 0.001
0.001 1.8 0.1–3.6 0.001
0.001 0.7 0.4–1.1 0.115
0.001 1.2 0.7–1.8 0.381
0.033 2.4 1.0–5.5 0.042
0.003 0.027
1
0.005 2.0 1.1–3.7 0.020
0.307 1.3 0.7–2.3 0.332
ph node metastasis, pCR=pathologic complete remission, pCRT=preoperative chemoradiotherapy,
[17]
Table 4
Cox regression hazard ratio for disease-free survival (LNM+).
Univariate analysis Multivariate analysis
HR CI (95%) P HR CI (95%) P
LN≥12 1.1 0.8–1.5 0.5 0.8 0.6–1.2 0.5
Sex 0.5 0.4–0.8 <0.001 0.6 0.4–0.8 <0.001
pTNM 3.4 2.5–4.6 <0.001 2.5 1.8–3.6 <0.001
pCRT 1.9 1.5–2.5 <0.001 1.6 1.1–2.1 0.001
CEA 1.9 1.5–2.4 <0.001 1.5 1.1–1.9 0.002
Histologic grade 1.6 1.1–2.4 0.011
LVI 1.5 1.2–1.9 0.002 1.5 1.2–2.1 <0.001
Preoperative symptom 2.3 1.4–3.7 0.001
Tumor location 1.3 0.9–1.9 0.133
CI= conﬁdence interval, HR=hazard ratio, LN= lymph node, LNM= lymph node metastasis, LVI= lymphovascular invasion, pCRT=preoperative chemoradiotherapy, pTNM=pathological tumor–node–-
metastasis.
Han et al. Medicine (2016) 95:38 Medicinesigniﬁcant difference in OS (73.8% vs 88.7%, P=0.001) was
observed between LNs≥8 and LNs<8 (Fig. 4). LN≥8, pTNM
stage, and histologic grade were signiﬁcant factors for DFS and
LNs≥8, age, pTNM stage, histologic grade, and American
Society of Anesthesiologists were signiﬁcant predictors for OS on
univariate analysis. On multivariate analysis, examination of
LNs≥8 provided a signiﬁcant beneﬁt in both DFS (HR=0.6,
95%CI: 0.4–1.1; P=0.042) andOS (HR=0.5, 95%CI: 0.2–0.9;
P=0.002) compared to LNs<8 (Tables 6, 7).4. Discussion
Adequate LN dissection not only reduces the likelihood of local
recurrence, but also enables the accurate staging of disease.
Therefore, there is concern that retrieval of insufﬁcient LNs may
result in understaging of the disease, which consequently leads to
suboptimal treatment. At this point in time, a minimum of 12
harvested LNs are recommended to accurately stage patients with
both colon and rectal cancer.[15,16] However, the studies
supporting this minimum number of 12 LNs are derived mainly
from studies on colon cancer.[6,7] Recent studies have proposed
that the LN yields in rectal specimens tend to be lower than those
in colon specimens.[11] Despite certain similarities in biology, the
treatment paradigms of colon and rectal cancer are signiﬁcantly
different, and due to this both have differing recurrence rates andTable 5










Histologic grade 2.8 1.9–4.1
LVI 1.6 1.2–2.1
Preoperative symptom 3.7 2.3–5.9
Tumor location 0.9 0.6–1.3
ASA=American Society of Anesthesiology, CEA=carcinoembryonic antigen, CI= conﬁdence interval, H
pCRT=preoperative chemoradiotherapy, pTNM=pathological tumor–node–metastasis.
6patterns. In rectal cancer, pCRT is employed in selected
patients to improve locoregional control and functional
outcomes,[8,18–20] but it has also been shown to signiﬁcantly
reduce the number of LNs harvested compared to those treated
without pCRT.[21–26] Our study aims to assess if the harvesting of
12 LNs in rectal cancer is appropriate for accurate prognositi-
cation, taking into account the presence or absence of pCRT.
Surgical specimens need to be dissected by qualiﬁed pathologist
with enough time to perform a thorough LN harvest if accurate
staging is to be achieved. The small size of retrieved LNs in
specimen is considered to be a limitation about standard methods
for examining LNs. Rodriguez-Bigas et al[27] reported that up to
70% of LNs with metastasis are <5mm in diameter. Such LNs
can more easily be missed if the pathologist applied a palpation
technique for identifying LNs. In an effort to improve LN harvest,
our institution routinely uses LN clearing solutions. Fat clearing
solutions (xylene and alcohol) have been adopted in many centers
to aid in LN retrieval, leading to an increase in their LN counts
from 6.1 to 18.9,[28] from 10.5 to 23.1,[29] and from 18.1 to
76.4.[30] The method with which LNs were harvested and
analyzed in our study is thus standardized and rigorous.
In the patients with metastatic LNs (LN+), regardless of pCRT
status, we found that the number of harvested LNs did not
prognosticate DFS or OS. As such, our data suggest that for the
patients with metastatic LNs, it may not be meaningful to requireMultivariate analysis
P HR CI (95%) P
0.179 1.1 0.7–1.6 0.692
<0.001 1.0 1.0–1.1 0.001
0.46
0.02
<0.001 5.1 3.5–7.3 <0.001
0.002
<0.001
<0.001 2.6 1.7–3.8 <0.001
0.002 1.6 1.2–2.2 0.003
<0.001 2.7 1.7–4.5 <0.001
0.806
R=hazard ratio, LN= lymph node, LNM= lymph node metastasis, LVI= lymphovascular invasion,
Figure 4. DFS and overall survival for 458 patients with pCRT and node negative by 8 harvested nodes. DFS=disease-free survival, pCRT=preoperative
chemoradiotherapy.
Han et al. Medicine (2016) 95:38 www.md-journal.comretrieval of more than 12 LNs, since LN positivity already such a
signiﬁcant prognostic factor for recurrence and survival.[4,5]
On the other hand, in patients without metastatic LNs (LN),
we have demonstrated that the number of harvested LNs was a
signiﬁcant prognostic factor, with an improvement in both DFS
and OS in patients with more than 12 harvested LNs. In the
subgroup of the LN patients without pCRT, LNs≥12
continued to be a signiﬁcant prognostic factor both for OS
and DFS. Thus, in this group of patients, a minimum of 12 LNs
would be necessary to avoid understaging and stage migration.
However, in the subgroup of LN patients with pCRT, LNs≥
12 was signiﬁcant only for DFS, but not for OS. This result may
be due to the effect of pCRT. Preoperative CRT inﬂuences LN
status due to tumoricidal effects and signiﬁcantly reduces the
number of harvested LNs.[9,24] The immune response and ﬁbrosis
of LNs after pCRT also contributes to the difﬁculty in
identiﬁcation of previously metastatic LNs in the pathologic
specimens.[22] Preoperative CRT may also decrease the size of
nonmetastatic LNs by 1 to 2mm[31,32] and thus may decrease the
likelihood of identiﬁcation in the surgical specimen.[33]
The optimal number of examined LNs after pCRT still has not
been fully elucidated. We attempted to investigate this further by
performing analysis for the patients who underwent pCRT
without LN metastasis. Using the maximal Chi-square method
based on survival data (M=3.4591, P=0.015), we derived that
the minimum number of LN required for examination that made
a prognostic difference was 8. For the patient who underwent
pCRT group with LN, examination of LN≥8 was a signiﬁcantTable 6
Cox regression hazard ratio for disease-free survival (LNM with pC
Univariate analysis
HR CI (95%)
LN≥8 0.6 0.4–1.0 0
pTNM <0
pCR 1
I 2.4 1.5–3.7 0
II 1.5 1.4–8.9 0
III 6.2 2.4–10.5 0
Histologic grade 1.9 1.0–3.5 0
CI= conﬁdence interval, HR=hazard ratio, LN= lymph node, LNM= lymph node metastasis, pCR
tumor–node–metastasis.
7prognostic factor both for OS andDFS. Based on our data, an LN
count of less than 8 in patients who have undergone pCRT and
found to be LN on pathology may be suboptimal and lead to
understaging. Therefore, more than 8 examined LNs in this
group of patients would be required to avoid stage migration.
Stage migration is an important factor to explain discrepancies
of survival within the same stage. One of the most important
reasons for stage migration in colorectal cancer is insufﬁcient LN
harvest. Given that the number of positive LNs identiﬁed is
fundamentally related to the total number of harvested LNs, a
proportion of patients classiﬁed as LN are likely to have been
understaged if the total number of LNs harvested was
inadequate.[34] Thus, evaluating a sufﬁcient number of LNs will
decrease the risk of missing a positive LN.
When patients with false-negative stage I/II are correctly
rediagnosed as stage III, the prognosis of both the stage I/II and
stage III patients will improve. This phenomenon – named after
the famous American comedian – is known as the Will Rogers
phenomenon.[35] This is due to 2 factors. First, the prognosis of
patients being rediagnosed is below average for the group (stage I/
II). Removing these patients will, by deﬁnition, raise the average
of the remaining patients group. Second, the prognosis of patients
being rediagnosed is above the current average of the group it is
entering (stage III). Adding it to the new set will, by deﬁnition,
raise the average survival and thus improve the prognosis. In our
study, there were 461 (79.1%) stage I/II patients in LNs<12
group, but 747 (60.1 %) stage I/II patients in LNs≥12 group.
The higher proportion of stage I/II patients in the LN<12 groupRT).
Multivariate analysis
P HR CI (95%) P
.030 0.6 0.4–1.1 0.042
.001 0.001
1
.001 2.3 1.3–3.6 0.001
.001 2.5 1.8–11.2 0.010
.001 6.0 1.1–11.7 0.001
.034 2.1 1.1–4.0 0.014
=pathologic complete remission, pCRT=preoperative chemoradiotherapy, pTNM=pathological
[4] KimNK, KimYW,Min BS, et al. Factors associated with local recurrence
Table 7
Cox regression hazard ratio for overall survival (LNM with pCRT).
Univariate analysis Multivariate analysis
HR CI (95%) P HR CI (95%) P
LN≥8 0.4 0.3–0.8 0.001 0.5 0.2–0.9 0.002
Age 1.1 1.05–1.1 0.017
pTNM <0.001 <0.001
pCR 1 1
I 2.4 0.2–2.4 0.001 1.2 0.3–4.0 0.001
II 2.1 0.6–6.9 0.001 3.3 1.0–10.8 0.001
III 1.7 1.4–5.1 0.001 1.8 1.4–5.2 0.001
Histologic grade 2.0 1.0–4.1 0.048
ASA 1.7 1.2–2.9 0.001
ASA=American Society of Anesthesiology, LN= lymph node, LNM= lymph node metastasis, pCR=pathologic complete remission, pTNM=pathological tumor–node–metastasis.
Han et al. Medicine (2016) 95:38 Medicineresults suggest there is the possibility that stage migration has
occurred due to insufﬁcient harvested LNs in those patients.
There are several limitations and inherent selection bias to our
study due to its retrospective nature. Although this study is the
largest so far to examine the impact of LN involvement in patients
with rectal cancer, the data may have been affected by
unmeasured confounding variables, including different surgical
techniques between surgeons, individual tumor biology, and
varying tumor responses to adjuvant treatment. Nevertheless, the
data that we present in this study hope to provide a baseline for
further studies to verify the optimal number of harvested LNs in
rectal cancer patients based on the presence or absence of pCRT.
This study suggests that the number of LNs harvested is an
important prognostic factor in rectal cancer patients with pCRT.
However, more importantly, it also suggested that the required
number of harvested LNs varies according to treatment setting.
The value of this study is in the analysis of patients based on
treatment settings, and we have derived the minimum values of
12 LNs in the non pCRT group and 8 LNs in the pCRT group.
We recommend that a different requirement for numbers of LN
harvested should be used depending on the presence or absence of
pCRT, and that this should be considered to be included in the
next versions of staging systems for rectal cancer. Certainly,
further successive studies are necessary to assess this further,
before the optimal number of harvested LN is determined.
5. Conclusion
Our study demonstrates that the number of LNs harvested is an
important prognostic factor in rectal cancer patients, and that
based on presence or absence of pCRT, a different number of LNs
may be optimal for staging and prognosis. Insufﬁcient LN retrieval
results in poorer prognosis inLN patients, and this is likely due to
stage migration. Examination of LNs≥12 and LNs≥8 should be
aimed to enable accurate staging and optimal treatment for the
non-pCRT group and pCRT group of patients, respectively.
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